Exchange: NYSE·Updated 04:10 PM EDT
News
all
press releases
CNMD Jumps 16% in a Month as Investors Assess Whether It Can Last
CNMD's 16% monthly rally is backed by stronger growth, margin gains and raised earnings guidance, but cash-flow and execution risks remain.
Zacks
More News
Is CNMD a Buy Now as Low Valuation Meets Persistent Execution Risk?
CNMD's low valuation and improved earnings outlook strengthen its appeal, but cash-flow pressure and execution risks keep the buy case measured.
Zacks
Can CONMED's Raised 2026 EPS Outlook Reinforce Its Growth Momentum?
CONMED raised its 2026 adjusted EPS outlook after a strong second quarter, but slower organic growth and higher financing costs keep the setup mixed.
Zacks
Here's Why You Should Retain CONMED Stock in Your Portfolio Now
CONMED's growth outlook is supported by Buffalo Filter, BioBrace and organic momentum, though slower AirSeal growth and tariffs remain key risks.
Zacks
SYK Stock Gains 3.8% Since March-End: What's Driving the Uptrend?
Stryker has gained 3.8% since March-end as Mako robotics, hospital capital demand and international growth drive momentum.
Zacks
CONMED Q2 Earnings and Revenues Beat Estimates, Gross Margin Expands
CNMD's Q2 earnings and revenues beat estimates, while margin growth and solid international sales support a higher 2026 EPS outlook.
Zacks
Conmed (CNMD) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Conmed (CNMD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks
Conmed (CNMD) Q2 Earnings and Revenues Top Estimates
Conmed (CNMD) delivered earnings and revenue surprises of +25.46% and +1.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
CONMED Corporation Reports Second Quarter 2026 Financial Results; Updates Full Year 2026 Guidance
CONMED Corporation (NYSE: CNMD) today reported financial results for the second quarter ended June 30, 2026 and updated its financial guidance for the full year ending 2026. Second Quarter 2026 Highlights(1) Sales of $343.5 million increased 0.3% year-over-year as reported and decreased 0.5% on a...
Business Wire
CONMED Expands AirSeal Robotic Solution for da Vinci 5 Hex Cannula
CNMD's FDA-expanded AirSeal indication adds da Vinci 5 hex cannula compatibility, supporting broader use across Intuitive Surgical's robotic systems.
Zacks

Advertisement|Remove ads.